The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA
Authors
Keywords
-
Journal
Cell Death Discovery
Volume 8, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-04-20
DOI
10.1038/s41420-022-01009-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MARCH5 requires MTCH2 to coordinate proteasomal turnover of the MCL1:NOXA complex
- (2020) Tirta Mario Djajawi et al. CELL DEATH AND DIFFERENTIATION
- MARCH5-dependent degradation of MCL1/NOXA complexes defines susceptibility to antimitotic drug treatment
- (2020) Manuel D. Haschka et al. CELL DEATH AND DIFFERENTIATION
- 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-mediated Apoptosis.
- (2020) Sha Jin et al. CLINICAL CANCER RESEARCH
- Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma
- (2020) Richa Bajpai et al. Nature Communications
- MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation
- (2020) Seiji Arai et al. eLife
- NOXA upregulation by the prohibitin‐binding compound fluorizoline is transcriptionally regulated by integrated stress response‐induced ATF3 and ATF4
- (2020) Sonia Núñez‐Vázquez et al. FEBS Journal
- Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition
- (2020) Alba Roca-Portoles et al. Cell Death & Disease
- The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA
- (2020) Alina Muenchow et al. Cell Death & Disease
- Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
- (2020) Shaji K Kumar et al. LANCET ONCOLOGY
- Small molecule ISRIB suppresses the integrated stress response within a defined window of activation
- (2019) Huib H. Rabouw et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma
- (2019) Esperanza M Algarín et al. HAEMATOLOGICA
- BH3-only proteins target BCL-xL/MCL-1, not BAX/BAK, to initiate apoptosis
- (2019) Kai Huang et al. CELL RESEARCH
- Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial
- (2018) Stephan Stilgenbauer et al. JOURNAL OF CLINICAL ONCOLOGY
- p53-independent Noxa induction by cisplatin is regulated by ATF3/ATF4 in head and neck squamous cell carcinoma cells
- (2018) Kanika Sharma et al. Molecular Oncology
- Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity
- (2018) Ryan S. Soderquist et al. Nature Communications
- Contribution of BH3-domain and Transmembrane-domain to the Activity and Interaction of the Pore-forming Bcl-2 Proteins Bok, Bak, and Bax
- (2018) Daniel Stehle et al. Scientific Reports
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
- (2018) Courtney D. DiNardo et al. BLOOD
- Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
- (2018) Adriana E. Tron et al. Nature Communications
- Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer
- (2017) Jeroen E Guikema et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Proteasome inhibitors in cancer therapy
- (2017) Elisabet E. Manasanch et al. Nature Reviews Clinical Oncology
- Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies
- (2016) AW Roberts et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
- (2016) Stephan Stilgenbauer et al. LANCET ONCOLOGY
- The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
- (2016) András Kotschy et al. NATURE
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
- (2016) M. Konopleva et al. Cancer Discovery
- Discoveries and controversies in BCL-2 protein-mediated apoptosis
- (2015) Janet H. Zheng et al. FEBS Journal
- Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
- (2015) J D Leverson et al. Cell Death & Disease
- Building blocks of the apoptotic pore: how Bax and Bak are activated and oligomerize during apoptosis
- (2013) D Westphal et al. CELL DEATH AND DIFFERENTIATION
- Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
- (2013) Peter E. Czabotar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Mechanisms of Action of Bcl-2 Family Proteins
- (2013) A. Shamas-Din et al. Cold Spring Harbor Perspectives in Biology
- Noxa: at the tip of the balance between life and death
- (2009) C Ploner et al. ONCOGENE
- ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells
- (2009) Q. Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More